TLR2 and myelodysplastic syndrome: In fact, some studies are already being developed, such as the clinical trial carried out with patients with low‐risk MDS, in which a TLR‐2 antagonist monoclonal antibody was used, which showed that 50% of patients showed hematological improvement and 2 achieved red blood cell transfusion independence [55], demonstrated in Table 2.